27277750|t|Co-delivery of pemetrexed and miR-21 antisense oligonucleotide by lipid - polymer hybrid nanoparticles and effects on glioblastoma cells
27277750|a|Combination therapy using anticancer drugs and nucleic acid is a more promising strategy to overcome multidrug resistance in cancer and to enhance apoptosis. In this study, lipid - polymer hybrid nanoparticles (LPNs), which contain both pemetrexed and miR-21 antisense oligonucleotide (anti-miR-21), have been developed for treatment of glioblastoma, the most aggressive type of brain tumor. Prepared LPNs have been well characterized by particle size distribution and zeta potential measurements, determination of encapsulation efficiency, and in vitro release experiments. Morphology of LPNs was determined by transmission electron microscopy. LPNs had a hydrodynamic size below 100 nm and exhibited sustained release of pemetrexed up to 10 h. Encapsulation of pemetrexed in LPNs increased cellular uptake from 6% to 78%. Results of confocal microscopy analysis have shown that co-delivery of anti-miR-21 significantly improved accumulation of LPNs in the nucleus of U87MG cells. Nevertheless, more effective cytotoxicity results could not be obtained due to low concentration of anti-miR-21, loaded in LPNs. We expect that the effective drug delivery systems can be obtained with higher concentration of anti-miR-21 for the treatment of glioblastoma.
27277750	0	11	Co-delivery	T169	C1705822
27277750	15	25	pemetrexed	T109,T121	C0210657
27277750	30	62	miR-21 antisense oligonucleotide	T114,T123,T130	C0079925
27277750	66	71	lipid	T109	C0023779
27277750	74	81	polymer	T104,T122	C0032521
27277750	82	102	hybrid nanoparticles	T073	C1450054
27277750	107	114	effects	T080	C1280500
27277750	118	130	glioblastoma	T191	C0017636
27277750	131	136	cells	T025	C0007634
27277750	137	156	Combination therapy	T061	C0009429
27277750	163	179	anticancer drugs	T109,T121	C0003392
27277750	184	196	nucleic acid	T114,T123	C0028606
27277750	238	258	multidrug resistance	T032	C0242640
27277750	262	268	cancer	T191	C0027651
27277750	284	293	apoptosis	T043	C0162638
27277750	303	308	study	T062	C2603343
27277750	310	315	lipid	T109	C0023779
27277750	318	325	polymer	T104,T122	C0032521
27277750	326	346	hybrid nanoparticles	T073	C1450054
27277750	348	352	LPNs	T122	C1713964
27277750	374	384	pemetrexed	T109,T121	C0210657
27277750	389	421	miR-21 antisense oligonucleotide	T114,T123,T130	C0079925
27277750	423	434	anti-miR-21	T114,T123,T130	C0079925
27277750	461	470	treatment	T169	C1522326
27277750	474	486	glioblastoma	T191	C0017636
27277750	497	507	aggressive	T191	C2945759
27277750	516	527	brain tumor	T191	C0006118
27277750	538	542	LPNs	T122	C1713964
27277750	575	588	particle size	T081	C0030608
27277750	589	601	distribution	T169	C1704711
27277750	606	620	zeta potential	T067	C0597697
27277750	621	633	measurements	T169	C0242485
27277750	652	665	encapsulation	T067	C2348438
27277750	666	676	efficiency	T081	C0013682
27277750	682	690	in vitro	T080	C1533691
27277750	691	710	release experiments	T062	C0681814
27277750	712	722	Morphology	T080	C0332437
27277750	726	730	LPNs	T122	C1713964
27277750	749	781	transmission electron microscopy	T059	C0678118
27277750	783	787	LPNs	T122	C1713964
27277750	794	806	hydrodynamic	T070	C2936194
27277750	807	811	size	T082	C0456389
27277750	839	856	sustained release	T169	C0391871
27277750	860	870	pemetrexed	T109,T121	C0210657
27277750	883	896	Encapsulation	T067	C2348438
27277750	900	910	pemetrexed	T109,T121	C0210657
27277750	914	918	LPNs	T122	C1713964
27277750	929	944	cellular uptake	T043	C0007613
27277750	972	1000	confocal microscopy analysis	T059	C0242842
27277750	1017	1028	co-delivery	T169	C1705822
27277750	1032	1043	anti-miR-21	T114,T123,T130	C0079925
27277750	1067	1079	accumulation	T033	C4055506
27277750	1083	1087	LPNs	T122	C1713964
27277750	1095	1102	nucleus	T026	C0007610
27277750	1106	1117	U87MG cells	T025	C0007634
27277750	1148	1160	cytotoxicity	T049	C0596402
27277750	1161	1168	results	T169	C1274040
27277750	1202	1215	concentration	UnknownType	C0678563
27277750	1219	1230	anti-miR-21	T114,T123,T130	C0079925
27277750	1242	1246	LPNs	T122	C1713964
27277750	1277	1298	drug delivery systems	T074	C0085104
27277750	1327	1340	concentration	UnknownType	C0678563
27277750	1344	1355	anti-miR-21	T114,T123,T130	C0079925
27277750	1364	1373	treatment	T061	C0087111
27277750	1377	1389	glioblastoma	T191	C0017636